Hospitals to put doctors' relationships with pharmaceutical companies under the microscope
The University of Colorado School of Medicine, National Jewish and Denver Health are all reviewing and tightening ethics rules as dozens of doctors defy reporting requirements for drug-company payments that can reach well into six figures.
National Jewish, most of whose doctors have dual roles with CU, said it is conducting its own rules review after a preliminary CU report said doctors were testing ethical boundaries and ignoring or disobeying disclosure rules.
"The status quo is no longer acceptable," said Richard Krugman, dean of the CU medical school.
Denver Health spokeswoman Dee Martinez said the hospital system is also reviewing its ethics policies for potential revision, given the recent outcry about pharmaceutical- company spending.
- Resisting the Healthcare Consolidation Frenzy
- Give Nurses in Wheelchairs a Chance
- 3 Better Ways to Market Bariatric Surgery
- HL20: George Halvorson—Expectations for Success
- Top 3 Health Plan Game Changers of 2013
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- AMCs React to Being Shut Out of Some Exchange Plans
- MGMA Urges 'End-to-End' ICD-10 Testing
- Q&A: Ardis Dee Hoven 'Optimistic' SGR Will Be Repealed
- MU Compliance Announcement Sparks Concern, Confusion